left ventricular diastolic dysfunction, [5] [6] [7] which also could predispose to AF. 12 Individuals with NAFLD have an increased risk of ischemic heart disease, 4 which is an established risk factor for AF. Additionally, intermittent hypoxia from sleep apnea is associated with an increased severity of NAFLD 13 and with increased atrial arrhythmogenicity and AF. 14 Finally, NAFLD is associated with autonomic dysfunction 15, 16 that may impact cardiac remodeling and play an important role in both initiating and maintaining AF. 17 Only a limited number of previous studies have related NAFLD, as defined on computed tomography (CT) or ultrasound, with prevalent or incident AF. The results of previous studies have been conflicting, with some studies identifying an association between elevated liver enzymes, but not imagingdefined NAFLD, with AF, whereas others reported that imaging-defined NAFLD was a predictor of AF in select cohorts. [18] [19] [20] [21] [22] Methods to prevent AF are incompletely understood, 23 and there are data to suggest that weight loss is associated with a reduced risk of AF. 24, 25 It is not known whether methods aimed at reducing hepatic fat may impact incident AF. Though the interactions between obesity, hepatic fat, and cardiovascular disease are complex, more studies are needed to better define the relations between HS and AF. Thus, we hypothesize that HS is associated with both prevalent AF and incident AF over up to 12 years of follow-up in
Framingham Heart Study (FHS) Offspring and Third Generation cohort participants, after accounting for known AF risk factors.
Methods Study Sample
Participants were drawn from the FHS Offspring and Third Generation cohorts who underwent measurement of liver fat by abdominal multi-detector computed tomography (MDCT) scan between 2002 and 2005 as a part of a substudy ( Figure 1 ). [26] [27] [28] Of the 3475 participants with adequate measures of liver fat on the MDCT study, we excluded participants for the following indications: 50 for missing covariates, 97 for missing serum alanine aminotransferase (ALT) or aspartate aminotransferase levels (AST), 39 for history of self-reported heavy alcohol use (defined as >14 drinks per week for women and >21 drinks per week for men), 29 and 1167 for age ≤45 years, given that the incidence of AF is low among younger adults. 30 The final sample included 2122 individuals. For the analysis of incident AF, we additionally excluded those with prevalent AF (n=62).
The institutional review boards of Boston University Medical Center and Massachusetts General Hospital approved of the protocol. All participants provided written informed consent. 
MDCT Protocol and Measurement of Liver Fat
The MDCT substudy has been described in detail previously. 27 Briefly, participants underwent abdominal imaging (LightSpeed Ultra; General Electric, Milwaukee, WI) in the supine position with 25 contiguous 5-mm slices (120 kVp, 400 mA; gantry rotation time, 500 ms; table feed, 3:1) starting at the upper edge of S1. A radiopaque phantom (Image Analysis, Lexington, KY) was placed under each participant and visualized on each image obtained. We obtained the mean MDCT Hounsfield units (HU) from 3 areas of the liver to determine the average liver HU. We calculated the liver phantom ratio (LPR) as the ratio between the average liver HU and the phantom HU as previously described. 31 As the LPR decreases, the amount of fat in the liver increases. We defined HS by an LPR ≤0.33, which was shown in our previous work to be highly sensitive and specific for detecting liver fat. 
Statistical Analysis
For the analysis of the association between liver fat and prevalent AF, we constructed multiple logistic regression models adjusting for covariates. We evaluated liver fat as a continuous variable using the ÀLPR (given that LPR decreases with increasing liver fat) and as a dichotomous value with an LPR ≤0.33 defined as HS. The base model was adjusted for age and sex alone. The multivariable model adjusted for age and sex and known risk factors for AF, 30 including current smoking, alcohol use, systolic blood pressure, diastolic blood pressure, antihypertensive medication use, diabetes mellitus, history of heart failure, and history of MI. Because liver fat is weakly correlated with BMI (r=0.25), 32 we included a third model, which added adjustment of BMI to the multivariable model. Results are reported as odds ratios (ORs) with 95% CIs. All logistic regression models were checked for goodness of fit using the Hosmer-Lemeshow goodness-of-fit test, and there was no evidence of lack of fit (P>0.05).
For the analysis of the association between liver fat and incident AF, we excluded any participant with diagnosed prevalent AF at baseline assessment. We constructed multivariable Cox (proportional hazards) regression models to assess the relationship between liver fat and incident AF over up to 12 years of follow-up. Censoring occurred at the time of death or end of follow-up. As with the prevalent AF analysis above, we evaluated liver fat as a continuous and dichotomous variable. We also evaluated the incidence of AF among those with HS (LPR ≤0.33) and increased ALT (defined as >19 U/L for women and >30 U/L for men) 34 at baseline. The multivariable models were adjusted for covariates in the same manner as in the prevalent AF analysis. We assessed the assumption of proportional hazards by calculating a supremum test on the basis of the cumulative sums of Martingalebased residuals. Results are reported as hazard ratios (HRs) with 95% CI. Age-and sex-adjusted cumulative AF incidence curves by HS status were generated for the graphical representation of data. Cumulative incidence curves were calculated and adjusted using the corrected group prognostic method. 35 The log-rank test was used to compare the AF cumulative incidence curves among those with and without HS at baseline. Given that we had 153 incident AF cases, a post-hoc power calculation revealed that we had 80% power to discover an adjusted HR of 1.27 or larger per presence versus absence of NAFLD at a 0.05 significance level. Analyses were performed in SAS software (version 9.3; SAS Institute Inc., Cary, NC). A 2-tailed probability value of <0.05 was considered statistically significant.
Results

Study Sample Characteristics
We present the baseline characteristics of the study sample (n=2122) in Table 1 . The sample included 1120 (53%) women, and the mean age was 59.0AE9.6 years. Overall, 20% of participants had HS on MDCT (defined by LPR). Those with HS had similar ages, but were less often women compared to those without HS. In general, compared to those without MDCT HS, individuals with HS had a higher prevalence of cardiovascular disease risk factors, including higher mean BMI ≥30 kg/m 2 and blood pressure, and higher percentages with hypertension, diabetes mellitus, and history of heart failure or past MI. Prevalence of AF among those with HS was 4% compared to 3% among those without HS.
Crude Incidence of AF by HS Status
Mean follow-up duration was 9.3 years in 19 235 person-years of observation. During up to 12 years follow-up, 153 participants developed AF ( Table 2 ). The overall incidence of AF was 7.95 cases per 1000 person-years. Incidence of AF among participants with HS on MDCT was 8.7 cases per 1000 personyears, whereas incidence of AF among participants without HS on MDCT was 7.8 cases per 1000 person-years.
Association Between Liver Fat and Prevalent AF
There was no significant association between fatty liver (measured as a continuous or dichotomous variable) and prevalent AF in age-and sex-adjusted or multivariable-adjusted models (Table 3) . Also, those participants with HS on MDCT and elevated ALT did not have an increased prevalence of AF compared to those without both HS and an elevated ALT.
Association Between Liver Fat and Incident AF
In age-and sex-adjusted and multivariable-adjusted models, there were no significant associations between continuous or dichotomous measures of HS and incident AF (Table 4) . Additionally, participants with both HS and elevated ALT did not demonstrate an increased incidence of AF in adjusted models compared to those without both HS and an elevated ALT. Cumulative hazard curves illustrate incidence of AF for participants with HS (LPR ≤0.33) compared to those without HS (LPR >0.33; Figure 2 ).
Discussion Principal Findings
In our community-based, longitudinal cohort study, we did not observe a statistically significant association between liver fat 
In the Context of the Previous Literature
Previous studies evaluating the association between liver fat and AF have mostly relied on blood-based surrogate markers of liver fat, including serum ALT, AST, or gamma glutamyl transpeptidase (GGT) levels. 19, 20, 36 GGT, a liver enzyme, was found to be associated with incident AF in the Atherosclerosis Risk in Communities study. 36 In a previous investigation of the FHS Original and Offspring cohorts, elevated ALT and AST were associated with increased incidence of AF, over 10 years of follow-up, adjusting for alcohol use. 20 There are several potential explanations for why we did not confirm the previous findings. In the previous FHS study, mean age of participants was 65AE10 years and those that developed AF were, on average, 6.8 years older at baseline compared to those who remained free of AF during the observation period. The incident rate of AF was 13.2 cases per 1000 person-years. Our study cohort was derived from the younger FHS participants in the Offspring and Third Generation cohorts who participated in the MDCT substudy. Though we excluded participants aged ≤45 years, the mean age of our sample was still relatively young at just under 60 years of age. Additionally, increases in ALT, AST, and GGT are not specific for liver fat. Elevated levels may be found in other conditions related to AF, such as alcohol use or heart failure, so it is possible that the previously reported associations between ALT, AST, or GGT and AF were driven by residual confounding from alcohol or comorbid medical conditions. Additional studies are required in older participants to examine how generalizable our findings are across age categories. Few studies have assessed the association between radiographically defined liver fat and AF. In a previous FHS investigation, there was no association observed between visceral abdominal fat and prevalent AF in multivariableadjusted models, but liver fat was not examined. 37 In a
German cohort study including community-dwelling individuals, elevated liver enzymes, but not ultrasound-defined HS, was associated with prevalent AF, which is in line with the findings of our study. 19 An investigation conducted using data from a Finnish registry of individuals with hypertension as well as age-and sex-matched controls showed that ultrasounddefined HS was associated with a higher odds of incident AF. 18 In our community-based cohort study, we did not demonstrate a significant association between liver fat and incident AF. There are a number of possible explanations for why our results differ from those observing an association between liver fat and AF. First, given that 51% of the participants in the Finnish study had hypertension, the results may not be generalizable to community-based samples with lower rates of Data are shown as odds ratios (95% CIs) per SD decrease of the liver phantom ratio (increasing liver fat). AF indicates atrial fibrillation; ALT, alanine aminotransferase; BMI, body mass index; HS, hepatic steatosis; LPR, liver phantom ratio; MV, multivariable; OR, odds ratio. *Multivariable adjustment included sex, age, systolic blood pressure, diastolic blood pressure, current smoking, use of antihypertensive medication, prevalent diabetes mellitus, history of heart failure, and history of myocardial infarction. Data are shown as hazard ratios (95% CIs) per SD decrease of the liver phantom ratio (increasing liver fat). AF indicates atrial fibrillation; ALT, alanine aminotransferase; BMI, body mass index; HR, hazard ratio; HS, hepatic steatosis; LPR, liver phantom ratio; MV, multivariable. *Multivariable adjustment included sex, age, systolic blood pressure, diastolic blood pressure, current smoking, use of antihypertensive medication, prevalent diabetes mellitus, history of heart failure, and history of myocardial infarction.
prevalent hypertension or other cardiovascular risk factors. Second, in contrast to our method of defining AF, in the Finnish study, AF was defined based on hospital discharge diagnoses. As such, it is possible that individuals with HS were more likely to be hospitalized for AF compared to those without HS, which may have introduced a systematic bias. Indeed, those with HS also tended to have a higher burden of comorbid cardiovascular disease, which may complicate the management of AF and require hospitalization instead of outpatient management. Importantly, there were only 153 incident cases of AF noted over 12 years of follow-up in our study. As such, we may not have had sufficient power to detect modest associations between liver fat and AF.
Strengths and Limitations
The major strengths of our investigation include the use of a well-phenotyped, community-dwelling sample within the context of a longitudinal cohort study with systematic follow-up procedures and detailed outcome ascertainment. However, a number of limitations are important to consider. First, MDCT is most sensitive and specific for moderate-to-severe liver fat and we cannot comment on the association between mild liver fat or more-severe forms of NAFLD, including steatohepatitis or liver fibrosis, and AF. Second, our sample was constituted middle-aged to older adults, largely of European descent. The generalizability of our findings to different races or ethnicities or older or younger age individuals is not known. Also, because the prevalence of AF is low, we had limited power. Finally, because AF is often asymptomatic, it is possible we missed AF during case ascertainment despite a careful assessment for outcomes.
Conclusion
Our findings, if confirmed, suggest that liver fat is not associated with AF over and above traditional AF risk factors in middle-aged to older, community-dwelling adults. Although FHS participants with increased liver fat had a higher burden of adverse cardiovascular traits, they did not have an increased prevalence of AF and were not at substantively increased risk for developing AF over a 12-year period. Additional prospective studies are needed to validate our findings. . Age-and sex-adjusted cumulative incidence curves for incident atrial fibrillation (AF) by presence or absence of hepatic steatosis. Participants with nonalcoholic fatty liver disease had a higher cumulative incidence of AF during follow-up, though results were not statistically significant (log-rank test, P=0.55).
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